I de tre langtids -, placebokontrollerede studier CARE, WOSCOPS og LIPID forekom markante ændringer af ALAT og ASAT (> 3 x øvre normalgrænse) med samme frekvens (≥ 1, 2%) i begge behandlingsgrupper.
In the three long-term, placebo- controlled clinical trials CARE, WOSCOP and LIPID, marked abnormalities of ALT and AST (> 3 x ULN) occurred at similar frequency (≤ 1.2%) in both treatment groups.